. 2019 Jun 6;10(7):1068–1081. doi: 10.1039/c9md00018f

Table 3. Albumin-binding small protein scaffolds.

Cargo		Albumin-binding molecule	Conjugate		Factor	Ref.
Type	τ _1/2	Albumin-binding molecule	Affinity	τ _1/2	Factor	Ref.
Exendin-4^†	30 min (i.v.)^a	ABD035 (18^a, 123^b, 16^c pM)	8^a, 40^b, 5^c pM	16 h (i.v.)^a	32^a	83
Exendin-4^†	30 min (i.v.)^a	ABD035 (18^a, 123^b, 16^c pM)	8^a, 40^b, 5^c pM	14 d (i.v.)^b	32^a	83
Fibronectin domain^§	n.a.	ABDCon (61^b, 75^c, 3200^d pM)	0.7^c, 1.8^d nM	193 h (i.v.)^b	n.a.	84
Fibronectin domain^§	n.a.	ABDCon (61^b, 75^c, 3200^d pM)	0.7^c, 1.8^d nM	60 h (i.v.)^d	n.a.	84
DARPins drug candidate^§	0.008 d (i.v.)^b	DARPins (91–266^a, 63–110^b, 11–21^c, 56–142^d, 77–185^e nM)	n.a.	2.7–20.7 d (i.v.)^b	>330^b	89
DARPins drug candidate^§	0.008 d (i.v.)^b		n.a.	21–82 h (i.v.)^d	>330^b	89
IL-1rα^§	2 min (i.v.)^d	AlbudAbs	34–600 nM^a,c,d	4.3 h (i.v.)^d	130^d	91
IFN-α2^§	1.2 h (i.v.)^a			22.6 h (i.v.)^a	19^a	92
IFN-α2^§	1.5 h (s.c.)^a			28.3 h (s.c.)^a	19^a	92
Anti-TNFR1^§	n.a.			3.3–23.2 h (i.v.)^d	n.a.	93
Exendin-4^†	2.5 h (s.c.)^c			6–10 d (s.c.)^c	58–96^c	94
Fab^§	n.a.	dsFv CA645 (54^a, 3.3^b, 4.6^c, 7.1^d, 162^f nM)	n.a.	7.9 d (i.v.)^b	n.a.	96, 97
Fab^§	n.a.	dsFv CA645 (54^a, 3.3^b, 4.6^c, 7.1^d, 162^f nM)	n.a.	2.6 d (i.v.)^d	n.a.	96, 97
Anti-TNF^§	35–54 min (i.v.)^d	Nanobody (22^c nM)	n.a.	2.2 d (i.v.)^d	91^d	99
Anti-IL-6R^§	4.3 h (i.v.)^b	Nanobody (22^c nM)	n.a.	1.7–6.6 d (i.v.)^b	9–37^b	100
Naïve VNAR^§	0.15 h (i.v.)^d	VNAR (E06) (3^a, 1^c, 6^d nM)	n.a.	22–25 h (i.v.)^a	140–220^d	102
				164–210 h (i.v.)^b
				21–33 h (i.v.)^d